# PAXLOVID® (nirmatrelvir-ritonavir) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/nirmatrelvir-ritonavir

> The FDA approved PAXLOVID® (nirmatrelvir-ritonavir), sponsored by PFIZER INC (PFE), on May 25, 2023.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is PAXLOVID® (nirmatrelvir-ritonavir) FDA approved?

Yes. The FDA approved PAXLOVID® (nirmatrelvir-ritonavir), sponsored by PFIZER INC (PFE), on May 25, 2023. FDA novel drug approvals: "Paxlovid | nirmatrelvir, ritonavir | 5/25/2023 | To treat mild-to-moderate COVID-19 in adults at high risk for progression to severe COVID-19Press ReleaseDrug Trials Snapshot" [Calendar and source filings](https://sec-api.dev/pdufa/nirmatrelvir-ritonavir)

Source: FDA novel drug approvals, https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2023 (retrieved 2026-11-16). Last confirmed 2026-11-16T22:20:01.192Z. Cite: https://sec-api.dev/pdufa/nirmatrelvir-ritonavir#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | PAXLOVID® (nirmatrelvir-ritonavir) |
| Codes |  |
| Sponsor | PFIZER INC (PFE) https://sec-api.dev/companies/pfe/catalysts |
| Indications |  |
| Modality | small_molecule |
| FDA designations | priority review |

## Timeline

### May 25, 2023: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- FDA novel drug approvals: "Paxlovid | nirmatrelvir, ritonavir | 5/25/2023 | To treat mild-to-moderate COVID-19 in adults at high risk for progression to severe COVID-19Press ReleaseDrug Trials Snapshot" https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2023
- openFDA Drugs@FDA: "NDA217188 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20230525, review_priority PRIORITY; sponsor_name PFIZER; product PAXLOVID (COPACKAGED) (NIRMATRELVIR; RITONAVIR)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA217188%22

### January 31, 2025: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA217188 SUPPL-8 (Efficacy): submission_status AP, submission_status_date 20250131, review_priority PRIORITY; sponsor_name PFIZER; product PAXLOVID (COPACKAGED) (NIRMATRELVIR; RITONAVIR)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA217188%22

### late 2025: topline data readout

- Status: scheduled. Date confidence: half. Stage: 2.
- First seen 2025-11-13, last confirmed 2025-11-13.
- Press release filed with the SEC (EX-99) (accession 0001104659-25-110829): "o Topline data expected by year-end 2025 from both the Phase 2 non-inferiority study and the single-arm study in PAXLOVID®-ineligible subjects" https://www.sec.gov/Archives/edgar/data/1130598/000110465925110829/tm2531045d1_ex99-1.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/nirmatrelvir-ritonavir.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "PAXLOVID® (nirmatrelvir-ritonavir) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/nirmatrelvir-ritonavir

```bibtex
@misc{secapidev_pdufa_nirmatrelvir_ritonavir_20261116,
  title        = {PAXLOVID® (nirmatrelvir-ritonavir) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/nirmatrelvir-ritonavir}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_nirmatrelvir_ritonavir_20261116","title":"PAXLOVID® (nirmatrelvir-ritonavir) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/nirmatrelvir-ritonavir","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
